Combined
endocrine therapy in premenopausal patients with metastases
Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 3 2000
Play
Audio Below:
The
other big question that I’m struggling with right now, Neil,
is in those women, whether you start with combined hormone therapy
or not. The dogma for metastatic breast cancer for hormone treatment,
as I understand it, has always been sequence, sequence, sequence,
sequence. You know, we did a lot of trials in the past that suggested
that combinations enhanced response rate, enhanced toxicity, and
didn’t really have any long-term impact on outcome. So, I think
that’s been our routine, you know, tamoxifen and then this
and then that. But, I think some of these trials that are being
done right now may actually bring that up for question again. And
I wonder whether we’re going to find out in the not too distant
future that we’ll actually be using combined hormone therapies
in some of these circumstances – and that two combinations
that I’m particularly thinking about, tamoxifen and an LHRH
agonist in the premenopausal women and then, of course, tamoxifen
and your choice of an aromatase inhibitor in the postmenopausal
women. And there are several trials that are tackling this as we
speak.
